Romain Pacaud, PhD

Title(s)Postdoctoral Scholar, Medicine
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Nantes University (France)PhD2016Medicine

    Collapse Overview 
    Collapse Interests

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Cheray M, Pacaud R, Nadaradjane A, Oliver L, Vallette FM, Cartron PF. Specific Inhibition of DNMT3A/ISGF3? Interaction Increases the Temozolomide Efficiency to Reduce Tumor Growth. Theranostics. 2016; 6(11):1988-1999. PMID: 27698935.
      View in: PubMed
    2. Pacaud R, Cheray M, Nadaradjane A, Vallette FM, Cartron PF. Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy. Theranostics. 2015; 5(1):12-22. PMID: 25553095.
      View in: PubMed
    3. Pacaud R, Sery Q, Oliver L, Vallette FM, Tost J, Cartron PF. DNMT3L interacts with transcription factors to target DNMT3L/DNMT3B to specific DNA sequences: role of the DNMT3L/DNMT3B/p65-NF?B complex in the (de-)methylation of TRAF1. Biochimie. 2014 Sep; 104:36-49. PMID: 24952347.
      View in: PubMed
    4. Pacaud R, Brocard E, Lalier L, Hervouet E, Vallette FM, Cartron PF. The DNMT1/PCNA/UHRF1 disruption induces tumorigenesis characterized by similar genetic and epigenetic signatures. Sci Rep. 2014 Mar 18; 4:4230. PMID: 24637615.
      View in: PubMed
    5. Cheray M, Pacaud R, Nadaradjane A, Vallette FM, Cartron PF. Specific inhibition of one DNMT1-including complex influences tumor initiation and progression. Clin Epigenetics. 2013 Jun 28; 5(1):9. PMID: 23809695.
      View in: PubMed